Business Wire

AUTODOC

26.3.2020 18:38:07 CET | Business Wire | Press release

Share
Autodoc donates EUR 50,000 for coronavirus research

Autodoc, Europe’s largest online retailer of car spare parts, is donating EUR 50,000 to the Stiftung Universitätsmedizin Essen foundation to support the fight against COVID-19. The researchers are studying the biology of the virus together with Chinese colleagues in a laboratory in Wuhan, China. The aim is to develop therapeutic options and preventive measures. As an internationally active company, Autodoc would like to become involved at a global level in the fight against the current pandemic.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005597/en/

Autodoc GmbH, based in Berlin, is an international company with online shops in 26 European countries. The employees come from all over the world. The current crisis also affects Autodoc employees, customers and suppliers to a high degree. Autodoc would like to take its responsibility as a company and actively participate in the fight against COVID-19. To this end, Autodoc is supporting researchers at the Universitätsmedizin Essen medical center and the Union Hospital in Wuhan in their search for special treatments against the virus.

According to Alexej Erdle, managing partner of Autodoc GmbH, “The corona crisis is a global pandemic that affects us all. We are an international company. That is why we feel a clear responsibility here to contribute to solving this crisis. Every day we see what can be achieved when people from different countries work together, just as the researchers from Essen and Wuhan are doing. Supporting their work is now the best way for us to do something that helps people all over the world, i.e. to fight this pandemic. With this donation, we want to set an example so that every individual as well as every company can think about how to get involved within the scope of their respective possibilities so that we can succeed in overcoming this challenge together.

Researchers against a global pandemic

Since the end of December 2019, the novel coronavirus, SARS-CoV-2, has been spreading at high speed. It is the trigger of the COVID-19 disease. The Institute of Virology and the Clinic for Infectiology at the Universitätsmedizin Essen medical center and the Clinic for Infectious Diseases at the Union Hospital in Wuhan have been working closely together for many years. In 2017, a joint research laboratory was founded in Wuhan. Numerous data and samples have been collected and recorded there since the beginning of the COVID-19 pandemic. Due to the number of cases in China, this results in a much larger database than is currently the case in Germany, for example. The laboratory is already in operation and well equipped, but money is still urgently needed to cover the running costs for material and personnel. Autodoc is now supporting the researchers’ work with a sum of EUR 50,000.

Jorit Ness, Managing Director of the University Medical Foundation, is very grateful for the support: “In the current situation, rapid help – which is at the same time sustainable – is essential. Thanks to the research cooperation between Essen and Wuhan, which has been in place for years, professional and established structures are now in place and can be used immediately. It is now important to make additional funds available for the evaluation of the extraordinarily large amounts of data and samples of disease cases. With the donation from Autodoc GmbH we have come a big step closer to our goal”.

Social commitment

Since its foundation in 2008, Autodoc has seen itself as an active part of society and is committed both ideologically and financially to helping disadvantaged social groups. Autodoc therefore regularly supports local initiatives in various European countries.

If you would like to support the research work in Essen and Wuhan, please visit https://www.universitaetsmedizin.de/forschung/corona/ and make a donation online. Or donate directly to:

Stiftung Universitätsmedizin Essen
Hufelandstraße 55
45147 Essen, Germany
E-mail: info@universitaetsmedizin.de
Internet: https://www.universitaetsmedizin.de/
Donation account:
IBAN: DE 0937 0205 0005 0005 0005
BIC: BFSWDE33
Reference: corona research

Autodoc GmbH – a brief profile

Autodoc GmbH is Europe’s leading online dealer for automotive spare parts. As the fastest-growing company in this sector with a 63% growth in turnover in the 2018 financial year to around EUR 415 million (2017: EUR 254 million), Autodoc is aiming to further expand its position. Thanks to its successful expansion, Autodoc is now represented in 25 other European countries in addition to Germany. Autodoc pursues a strong customer focus through social media activities, technical support in the respective national language and demand-oriented product range composition with currently almost 2.5 million products from 545 brand manufacturers for 128 car brands. The online retailer offers a wide range of products from brake systems, body parts, shock absorbers and springs, exhaust systems, interior elements, steering systems and clutches to air conditioning systems, heaters, repair kits and engine oil. In June 2018, the company celebrated its tenth anniversary. Autodoc GmbH is based in the Berlin district of Lichtenberg and is fully owner-managed. In May 2019, the company opened a representative office on Kurfürstendamm in addition to its headquarters.

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 09:00:00 CEST | Press release

NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye